Dopamine injection to improve blood flow in shock patients

Dopamine is a medication used as a continuous intravenous infusion to improve heart function and blood flow in patients experiencing shock caused by low cardiac output or distributive causes. It acts as a vasopressor and cardiac stimulant to help restore hemodynamic stability, typically administered in intensive care settings under close monitoring.

Dopamine hydrochloride injections are approved for use in adults and pediatric patients to improve hemodynamic status in distributive shock or shock due to reduced cardiac output. It is intended for use in hospital intensive care units and critical care environments where close cardiovascular monitoring is possible.

Dopamine hydrochloride

Dopamine is a naturally occurring catecholamine and precursor to norepinephrine. It works by stimulating dopamine receptors and adrenergic receptors in the heart and blood vessels, leading to increased heart rate, contraction strength, and improved blood flow. At different doses, dopamine affects vascular tone and cardiac output to support blood pressure and organ perfusion during shock.

General Dosing for Adults and Pediatric Patients

• Starting dose: 2 to 5 mcg/kg/min continuous intravenous infusion.
• Titration: Increase dose in increments of 5 to 10 mcg/kg/min based on patient response.
• Maximum dose: Do not exceed 50 mcg/kg/min.

Preparation and Administration

• Dopamine Injection (40 mg/mL) must be diluted in sterile intravenous fluids such as 0.9% sodium chloride or 5% dextrose before infusion.
• Dopamine in 5% dextrose is available as a premixed solution and does not require dilution.
• Administer via large vein using an infusion pump, preferably in an ICU setting.
• Correct hypovolemia, acidosis, and hypoxia before starting dopamine.
• Discontinuation should involve gradual tapering of the infusion rate while providing intravenous fluids to avoid hypotension.

Infusion Rate Calculation

Infusion Rate (mL/hour) = [Dose (mcg/kg/min) × Weight (kg) × 60] ÷ Concentration (mcg/mL)

Dopamine is contraindicated in patients with pheochromocytoma.

Serious Risks and Precautions

• Tissue ischemia: Dopamine can cause severe peripheral and visceral vasoconstriction, especially if given to patients with hypovolemia. Correct hypovolemia before starting treatment and monitor extremities closely for signs of ischemia or gangrene.
• Extravasation risk: Dopamine can cause tissue necrosis if it leaks outside the vein. Infuse into a large vein and frequently check the infusion site.
• Cardiac arrhythmias: Dopamine may induce arrhythmias; continuous ECG monitoring is recommended.
• Hypotension upon abrupt discontinuation: Gradually taper the infusion rate while expanding blood volume with fluids to avoid sudden drops in blood pressure.
• Severe hypersensitivity: The injection contains sodium metabisulfite, which can cause life-threatening allergic or asthmatic reactions in sensitive individuals.

Common and Serious Adverse Reactions

• Localized vasoconstriction at the infusion site, sometimes causing extravasation injury.
• Cardiac disorders: anginal pain, palpitations, arrhythmias.
• Gastrointestinal: nausea, vomiting.
• Metabolic: azotemia.
• Nervous system: headache, anxiety.
• Respiratory: dyspnea.
• Skin: piloerection.
• Vascular: hypertension.

Significant Drug Interactions

• Halogenated anesthetics (desflurane, enflurane, isoflurane, sevoflurane): May sensitize heart to dopamine leading to ventricular arrhythmias and hypertension. Monitor cardiac rhythm.
• Monoamine oxidase (MAO) inhibitors (isocarboxazid, phenelzine, tranylcypromine, rasagiline, selegiline, linezolid): Can cause severe hypertension and arrhythmias; reduce dopamine dose to 10% of normal if recently treated with MAO inhibitors.
• Tricyclic antidepressants (amitriptyline, desipramine, doxepin, imipramine, nortriptyline): Increase risk of hypertension; monitor blood pressure.
• Vasopressors (norepinephrine, epinephrine, oxytocin): Combined use may cause severe hypertension; monitor blood pressure.

Pregnancy

There are no adequate human data on dopamine use in pregnancy. Animal studies showed adverse developmental effects at doses lower than the human starting dose. Hypotension due to shock poses a significant risk to mother and fetus; treatment should not be withheld when medically necessary.

Dopamine may cause severe maternal hypertension if used with oxytocic drugs during labor.

Lactation

There are no data on dopamine presence in human milk or effects on breastfed infants.

Manifestations of overdose may include severe hypertension, arrhythmias, and tissue ischemia. Management includes immediate discontinuation of dopamine infusion and supportive care. Monitor cardiovascular and tissue perfusion status closely.

Store all dopamine products according to the specific manufacturer’s instructions. For injection concentrates, store in original container and dilute before use. Premixed dopamine in dextrose is typically supplied in sealed flexible plastic containers; remove outer wrap only when ready to administer and do not use if damaged.

Liquid homeopathic dopamine products should be stored in a cool, dry place.